Advanced Search: Endocrine

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201911082

A randomized Phase I/II trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) versus fulvestrant and abemaciclib alone (FA) for endocrine-resistant, hormone receptor positive, HER2 negative metastatic breast cancer (FAC vs FA)

202107015

TK IMPACT: Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) with or without the Addition of DiviTum(R) Serum Thymidine Kinase 1 (TK1) Activity Testing: Physician Decision Impact Study

202007216

EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non- Breast Cancers

202007074

A Phase 1/2, open-label, dose escalation, and cohort expansion clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ARV-471 in patients with ER+/HER2- locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting

202108130

A Phase III, Double-blind, Randomised Study to Assess Switchingto AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitors(Palbociclib or Abemaciclib) vs Continuing NSAI + CDK4/6 Inhibitorsin HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Clinical or Radiological Progression During 1L Treatment with NSAI +CDK4/6 Inhibitor